| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Didemnin B targets elongation factor 1-alpha (eEF1A), blocking aminoacyl-tRNA accommodation on the ribosome. This inhibition of protein synthesis is the primary mechanism underlying its antiviral and antitumor activities. It also activates caspase, thereby inducing apoptosis.
|
|---|---|
| ln Vitro |
Didemnin B exhibits antitumor efficacy against M5076 sarcoma, P388 leukemia, and mirine B16 melanoma [1].
In vitro, didemnin B is a potent inhibitor of L1210 leukemia cell growth. It prevents upregulation of GRP78 protein in HepG2 cells at 80 nM, in association with sustained inhibition of protein synthesis. It exhibits strong antitumor efficacy against various cancer cell lines. |
| ln Vivo |
A strong inhibitor of L1210 growth is didemnin B [1].
In vivo, didemnin B has demonstrated antitumor efficacy against M5076 sarcoma, P388 leukemia, and murine B16 melanoma. It is a potential anticancer, antiviral, and immunosuppressive agent. |
| Enzyme Assay |
In vitro assays for didemnin B typically measure its ability to inhibit protein synthesis. Cells are treated with the compound, and the incorporation of radiolabeled amino acids into proteins is measured. The compound's binding to eEF1A can be assessed using pull-down or surface plasmon resonance assays.
|
| Cell Assay |
Cell-based assays for didemnin B involve treating various cancer cell lines with the compound and measuring cell viability, proliferation, and apoptosis. The compound's ability to inhibit protein synthesis and induce cell death is assessed.
|
| Animal Protocol |
In vivo animal studies for didemnin B typically involve administration to mouse models of cancer. Tumor growth inhibition, survival, and pharmacodynamic endpoints are evaluated. The compound's efficacy against M5076 sarcoma, P388 leukemia, and B16 melanoma has been demonstrated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of didemnin B have been studied in preclinical models. The compound has a molecular formula of C₅₇H₈₉N₇O₁₅ and a molecular weight of 1112.37 g/mol. It is a cyclic depsipeptide with complex pharmacokinetic properties. The intravenous LD50 in rats is 860 pg/kg, and in mice is 1530 pg/kg.
|
| Toxicity/Toxicokinetics |
Toxicity Data
Rat (intravenous injection): LD50: 860 pg/kg Mice (intravenous injection): LD50: 1530 pg/kg Dogs (intravenous injection): LD50: 418 g/kg The toxicological profile of didemnin B has been evaluated in preclinical studies. The compound has demonstrated potent activity, and its toxicity profile is consistent with its mechanism of action as a protein synthesis inhibitor. The intravenous LD50 in dogs is 418 g/kg. |
| References | |
| Additional Infomation |
Didemnin B is a Didemnin-like compound that functions as a metabolite. It has been reported to exist in Trididemnum cyanophorum, Trididemnum solidum, and other organisms with relevant data. Didemnin B is a cyclic peptide extracted from the Caribbean sea squirt Trididemnum cyanophorum. Didemnin B activates caspase, thereby inducing apoptosis, and inhibits eukaryotic elongation factor 2 (eEF-2)-dependent translocation, thereby suppressing protein synthesis. This compound also possesses immunosuppressive and antiviral properties. (NCI04)
Didemnin B is a marine natural product with significant research value. It is not approved for human therapeutic use but serves as a lead compound for the development of anticancer and antiviral agents. Its mechanism of action as an eEF1A inhibitor makes it a valuable tool for studying protein synthesis. |
| Molecular Formula |
C57H89N7O15
|
|---|---|
| Molecular Weight |
1112.37
|
| Exact Mass |
1111.64
|
| CAS # |
77327-05-0
|
| PubChem CID |
122651
|
| Appearance |
White to off-white solid powder
|
| Density |
1.24g/cm3
|
| Boiling Point |
1274.4ºC at 760 mmHg
|
| Flash Point |
724.5ºC
|
| Index of Refraction |
1.569
|
| LogP |
3.178
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
79
|
| Complexity |
2150
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]3CCCN3C(=O)[C@H](C)O)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O
|
| InChi Key |
KYHUYMLIVQFXRI-SJPGYWQQSA-N
|
| InChi Code |
InChI=1S/C57H89N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-36,39-44,46-47,49,65-66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,35-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1
|
| Chemical Name |
(2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-1-[(2S)-2-hydroxypropanoyl]-N-methylpyrrolidine-2-carboxamide
|
| Synonyms |
NSC-325319; NSC 325319; Didemnin B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~89.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8990 mL | 4.4949 mL | 8.9898 mL | |
| 5 mM | 0.1798 mL | 0.8990 mL | 1.7980 mL | |
| 10 mM | 0.0899 mL | 0.4495 mL | 0.8990 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
